HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

Client Profiles

 

CellceutixCellceutix
OTC: CTIX
www.cellceutix.com
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly-traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Cellceutix’s psoriasis drug candidate Prurisol completed a Phase 2 trial and Cellceutix recently launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is preparing for a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of oral mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first cohort of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.

Yahoo Data and NewsCompany Web Site

ICON LEGEND
Yahoo Data and News
 Yahoo Finance Data & News
Company Profile Company Profile (PDF)
Company Web Site Company Web Site

News and Updates

Remark Media Appoints Brett Ratner to its Board of Directors
LAS VEGAS, March 1, 2017 -- Remark Media, Inc. (MARK), a global digital media technology company, announced it has appointed Brett Ratner to its board of directors. Directors Robert Goldstein and Jason Strauss are resigning from the board effective today. (full story)

Ritter Pharmaceuticals Announces Collaboration with University of British Columbia
LOS ANGELES, CA--(Feb 13, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with Dr. B Brett Finlay from the Michael Smith Laboratories at the University of British Columbia ("UBC") to study the role of the microbiome and RP-G28 in environmental enteropathy ("EE"). (full story)

Remark Media Partners with Alibaba Cloud to Launch Enterprise Data Services Solution
LAS VEGAS, Jan. 23, 2017 -- Remark Media, Inc. (MARK), a global digital media technology company, announced it has partnered with Alibaba Cloud to provide customers with a new business-to-business (B2B) data solution. Available now, the Enterprise Data Services Solution includes data on tens of millions of businesses in China. It offers real-time risk insights; enterprise development analysis; investor, partner and customer targeting; customized data packages; and more. (full story)

More Articles
 

Upcoming Events

There are no events to display at this time.
Complete Events List
 

Remark MediaRemark Media, Inc.
NASDAQ: MARK
www.remarkmedia.com
Remark Media, Inc. (MARK) owns, operates and acquires innovative digital media properties across multiple verticals that deliver culturally relevant, dynamic content that attracts and engages users on a global scale.  The company leverages its unique digital media assets to target the Millennial demographic, which provides it with access to fast-growing, lucrative markets.  The company is headquartered in Las Vegas, Nevada, with additional operations in Los Angeles, California and in Beijing, Shanghai, Hangzhou and Chengdu, China. For more information, please visit the company's website at www.remarkmedia.com.
Yahoo Data and NewsCompany Web Site

Ritter PharmaceuticalsRitter Pharmaceuticals, Inc.
NASDAQ: RTTR
ritterpharmaceuticals.com
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of gut modulation into applications intended to have a meaningful impact on a patient’s health.
Ritter’s leadership team has extensive biotechnology expertise in discovering, developing and commercializing therapeutic products. We have attracted a scientific team comprised of innovative researchers who are world renowned in their knowledge and understanding of the host-microbiome. Combined, our expertise is leading the way in the understanding of the host gut microbiome and the discovery in novel microbiome modulators.
Our lead compound, RP-G28 is currently under development for the treatment of lactose intolerance. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. The product stimulates the growth of lactose-metabolizing bacteria in the colon, which reduces lactose-derived gas production, and thereby mitigates the symptoms of lactose intolerance in the process.
Yahoo Data and NewsCompany Web Site

 

lower_banner

lower_banner-02

  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved